Bayer Completes Phase II Study On BAY 94-9172 In Alzheimer's Disease Imaging

Bayer Schering Pharma AG, Germany, has completed its first global Phase II study analyzing the sensitivity and specificity of BAY 94-9172 (AV1/ZK) using positron emission tomography (PET) in patients with probable Alzheimer's disease compared to healthy volunteers. BAY 94-9172 binds to the beta amyloid protein in the brain, a pathological hallmark of Alzheimer's disease. More at...

FDA Requests Labeling Change For Leukotriene Modifiers

The U.S. Food and Drug Administration provided further updated safety information on a class of asthma drugs known as leukotriene modifiers. The FDA has requested that manufacturers include a precaution in the drug prescribing information (drug labeling) regarding neuropsychiatric events (behavior, mood changes) that have been reported in some persons taking montelukast (Singulair), zafirlukast (Accolate), and zileuton (Zyflo and Zyflo CR). More at...

To Promote Cardiovascular Health, Tulane University Partners With South American Universities

To Promote Cardiovascular Health, Tulane University Partners With South American Universities
Cardiovascular disease researchers at Tulane University are partnering with faculty at the University of Buenos Aires, Argentina, to establish the South American Center of Excellence in Cardiovascular Health. The center has received a five-year, $2.3 million dollar grant from the National Heart, Lung and Blood Institute of the National Institutes of Health. The focus of the center's activities will be on cardiovascular health research and education.